From PCR to Biomarkers: A Case Study Evaluation of Bioanalytical Challenges in Cell and Gene Therapy Products

From PCR to Biomarkers: A Case Study Evaluation of Bioanalytical Challenges in Cell and Gene Therapy Products
March 15, 2022 Ariadne Solutions

From PCR to Biomarkers: A Case Study Evaluation of Bioanalytical Challenges in Cell and Gene Therapy Products

April 5, 2022 | 10 am ET

While new and existing technologies and tools have come to support the bioanalysis needs of cell and gene therapy products, several challenges remain unaddressed. Molecular testing platforms, such as qPCR, ddPCR, NGS are critical for cell and gene therapy products enabling the quantification of key endpoints such as gDNA, mRNA, %editing, etc. Although these approaches have been around for decades, if not longer, their application in bioanalytical assays for this category of therapies is a more recent development. Additionally, the development of cell and gene therapy products had also increased the importance and scrutiny of biomarker assays to support the pharmacodynamics of the drug candidate. However, specific guidance for validation from regulatory authorizes and sharing of troubleshooting approaches are limited. During this webinar, we will discuss bioanalytical platforms typically used during the development of cell and gene therapy products and provide a variety of case studies highlighting troubleshooting and risk assessment/acceptance criteria examples.

You will learn:

  • What platforms are being used for cell and gene therapy programs and why
  • How are acceptance criteria applied when specifications from health authorities are not available
  • For biomarkers – when are CLIA assays appropriate and when would FDA regulated fit-for-purpose assays provide a better approach